PROGNOSTIC VALUE OF IL-6 AND IL-8 FOR RISK STRATIFICATION IN COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN
- Авторы:Natalya Anatolyevna Belykh, Natalya Aleksandrovna Anikeeva, Anastasia Yuryevna Zhuleva , Sultanova Nafisa Sabirovna, Avezova Guloyim Sattarovna
- Дата публикации:March 24, 2026
- Тип:Статья
- DOI: 10.64156/mju.9028 Скопировано
- Том / № Выпуска:Том 1 №2 (2026)
Аннотация
Abstract. The search for prognostic biomarkers for the severity of community-acquired pneumonia (CAP) in children is of significant clinical interest. The aim of the study was to evaluate the serum interleukin-6 (IL-6) and interleukin-8 (IL-8) concentration in children with CAP depending on the severity of the disease. Patients and methods. The serum IL-6, IL-8 and procalcitonin (PCT) and C-reactive protein (CRP) concentrations were determined by ELISA upon admission in 37 hospitalized children (13 with severe CAP and 24 with non-severe CAP). Results. The serum IL-6 and IL-8 concentrations were significantly higher in the severe CAP group, compared of the non-severe CAP group by 2.2 and 3.6 times, respectively. Direct correlations of moderate strength were revealed between the severity of the disease and the serum IL-6 (r=0.68) concentration and IL-8 (r=0.57) respectively (p<0.0001). The serum IL-6 and IL-8 concentration correlated with each other (r=0.49, p=0.002) and with other inflammatory markers: serum IL-6 concentration with leukocytosis (r=0.42), neutrophilia (r=0.49), and PCT (r=0.53); serum IL-8 concentration – with PCT (r=0.49) and CRP (r=0.35). Conclusion. These data confirm the involvement of IL-6 and IL-8 in the pathogenesis of the systemic inflammatory response in CAP. Serum cytokines concentration are promising prognostic biomarkers for risk stratification of severe community-acquired pneumonia in children.
Keywords: community-acquired pneumonia, biomarkers, children, interleukin-6, interleukin-8.
Аннотация. Поиск прогностических биомаркеров тяжести внебольничной пневмонии (ВП) у детей представляет значительный клинический интерес. Цель: оценка уровня интерлейкина-6 (IL-6) и интерлейкина-8 (IL-8) в сыворотке крови у детей с ВП в зависимости от тяжести течения заболевания. Материалы и методы. У 37 госпитализированных детей (13 — с тяжелой ВП и 24 — с нетяжелой ВП) при поступлении определяли сывороточные концентрации IL-6, IL-8 и прокальцитонина (PCT) и С-реактивного белка (СРБ) методом ИФА. Результаты. Уровни IL-6 и IL-8 были достоверно выше в группе тяжелой ВП, превышая показатели группы пациентов с нетяжелой ВП в 2,2 и 3,6 раза соответственно. Выявлены прямые корреляционные связи средней интенсивности между тяжестью заболевания и уровнем IL-6 (r=0,68, p<0,0001) и IL-8 (r=0,57, p<0,0001). Концентрация IL-6 и IL-8 коррелировали друг с другом (r=0,49, p=0,002), а также с другими маркерами воспаления: уровень IL-6 — с лейкоцитозом (r=0,42), нейтрофилезом (r=0,49) и уровнем PCT (r=0,53); IL-8 — с PCT (r=0,49) и СРБ (r=0,35). Выводы: Полученные данные подтверждают вовлеченность IL-6 и IL-8 в патогенез системного воспалительного ответа при ВП. Уровни этих цитокинов в сыворотке крови являются перспективными прогностическими биомаркерами для стратификации риска тяжелого течения внебольничной пневмонии у детей.
Ключевые слова: внебольничная пневмония, биомаркеры, дети, интерлейкин-6, интерлейкин-8.
Rezyume. Bolalarda shifoxonadan tashqari pnevmoniya (ShTP) og‘irligini bashoratlovchi biomarkerlarni izlash muhim klinik ahamiyatga ega.Maqsad: shifoxonadan tashqari pnevmoniya bilan kasallangan bolalarda kasallik kechishining og‘irligiga qarab qon zardobida interleykin-6 (IL-6) va interleykin-8 (IL-8) darajasini baholash.Materiallar va usullar. Shifoxonaga yotqizilgan 37 nafar bolada (13 nafari — og‘ir ShTP, 24 nafari — og‘ir bo‘lmagan ShTP) qabul paytida qon zardobida IL-6, IL-8, prokaltsitonin (PCT) va C-reaktiv oqsil (CRO) miqdori immunoferment tahlil (IFT) usuli yordamida aniqlandi.Natijalar. Og‘ir kechuvchi ShTP guruhi bolalarida IL-6 va IL-8 darajalari og‘ir bo‘lmagan ShTP guruhi ko‘rsatkichlariga nisbatan mos ravishda 2,2 va 3,6 baravar yuqori ekanligi aniqlandi. Kasallik og‘irligi bilan IL-6 (r = 0,68; p < 0,0001) va IL-8 (r = 0,57; p < 0,0001) darajalari o‘rtasida o‘rtacha kuchdagi to‘g‘ridan-to‘g‘ri korrelyatsion bog‘liqliklar aniqlangan. IL-6 va IL-8 konsentratsiyalari o‘zaro ham korrelyatsiyaga ega bo‘lib (r = 0,49; p = 0,002), shuningdek yallig‘lanishning boshqa markerlari bilan ham bog‘liqlik ko‘rsatdi: — IL-6 darajasi leykotsitoz (r = 0,42), neytrofilyoz (r = 0,49) va PCT darajasi (r = 0,53) bilan;
— IL-8 darajasi PCT (r = 0,49) va CRO (r = 0,35) bilan korrelyatsiya qilgan.Xulosalar. Olingan natijalar shifoxonadan tashqari pnevmoniyada tizimli yallig‘lanish javobi patogenezida IL-6 va IL-8 ning ishtirokini tasdiqlaydi. Ushbu sitokinlarning qon zardobidagi darajalari bolalarda shifoxonadan tashqari pnevmoniyaning og‘ir kechish xavfini stratifikatsiya qilish uchun istiqbolli prognostik biomarkerlar hisoblanadi.
Kalit so‘zlar: shifoxonadan tashqari pnevmoniya, biomarkerlar, bolalar, interleykin-6, interleykin-8.
References
- Izyurova N.V., Savochkina A.Yu., Uzunova A.N., Nokhrin D.Yu. Cytokine profile in community-acquired pneumonia in children // Medical Immunology. - 2022. - Vol. 24, No. 5. - Pp. 943-954. DOI: 10.15789/1563-0625-CPI-2538
- Malanicheva T.G., Mozhgina S.S., Agafonova E.V. Local cytokine profile and cytological status in children with community-acquired pneumonia occurring against the background of reduced resistance of the body // Russian Bulletin of Perinatology and Pediatrics. – 2017. – Vol. 62, No. 5. – P. 139-143. DOI: 10.21508/1027–4065–2017–62–5–139–143
- . On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2023: State report. – Moscow: Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 2024. – 364 p.
- Pneumonia (community-acquired). Clinical guidelines – 2022-2023-2024 (January 18, 2022): Approved by the Ministry of Health of the Russian Federation / Union of Pediatricians of Russia. – Moscow, 2022.
- Simbirtsev A.S. Cytokines in the pathogenesis and treatment of human diseases. St. Petersburg: Foliant, 2018, 512 p.
- Karakioulaki M., Stolz D. Biomarkers in pneumonia – beyond procalcitonin. Int J Mol Sci. 2019, Vol. 20, no. 8, pp. 2004. DOI: 10.3390/ijms20082004
- Tanaka T., Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res., 2014, Vol. 2, no 4, pp. 288-294. DOI: 10.1158/2326-6066.CIR-14-0022
- Wang H., Zhang Y., Zhao C., Yun Peng, Wenqi Song, Weihan Xu et al. Serum IL-17A and IL-6 in pediatric Mycoplasma pneumoniae pneumonia: implications for different endotypes. Emerg Microbes Infect., 2024, Vol. 13, no 1, pp. 2324078. DOI: 10.1080/22221751.2024.2324078
- Weidhase L., Wellhöfer D., Schulze G., Kaiser T., Drogies T., Wurst U., Petros S. Is interleukin-6 a better predictor of successful antibiotic therapy than procalcitonin and C-reactive protein? A single center study in critically ill adults. BMC Infect Dis., 2019, Vol. 19, pp.150. DOI: 10.1186/s12879-019-3800-2
- Yao G., Ma C., Liu J., Zexuan Sun, Botao Wei. Interleukin-6 serum levels are independently associated with severeadenovirus pneumonia in children: a cross-sectional study. Transl Pediatr., 2022, Vol. 11, No. 12, pp. 1962-1971. DOI: 10.21037/tp-22-585.